Macular Edema Clinical Trial
Official title:
Intraoperative Utility of Brilliant Blue g (Bbg) and Indocyanine Green (Icg) Assisted Chromovitrectomy
Intravitreal dyes are intended to make the surgical extraction of the Internal limiting
membrane (ILM) safer and more complete. However, the search for an adequate vitaly dye is
ongoing. The most commonly used vital dye is Indocyanine green (ICG), although it is not
approved for intravitreal use and has been associated with ocular toxicity. The reason for
its continued popularity seems to be that it stains the ILM better than the approved and less
toxic alternative substances Brilliant Blue G (BBG) and Trypan blue (TB). According to
anecdotal reports from surgeons, another reason for ICGs popularity may be the fact that it
seems to make ILM removal easier. Ultimately, the intention of the investigators research is
to identify possible modifications to existing dyes to reach improved intraoperative dye
utility combined with a favorable safety profile.
Protocol was amended and approved concerning additional use of basal membrane of deceased
donors.
The human retina is a light-sensitive tissue lining the inner surface of the posterior
segment of the eye. It is a complex, layered structure containing the photoreceptors and
several layers of neurons. Proper retinal function requires a smooth interface between the
retina and the adjoining vitreous body (vitreous), a gelatinous and transparent substance
occupying the cavity of the posterior ocular segment. The innermost of the retinal layers, a
basement membrane called Inner limiting membrane (ILM), represents the boundary between the
retina and the vitreous. Excessive contact between the ILM and the vitreous leads to
vitreoretinal traction and represents a common cause of ocular pathology: The vitreous
adheres to the ILM and shearing forces are conveyed to the retina. Vitreoretinal traction
concentrates around the Macula lutea, the small area in the center of the retina which is
responsible for central vision. It may be associated with significant visual disturbance as
it creates retinal folds, provokes retinal edema and epiretinal metaplastic membranes through
the liberation of inflammatory messenger substances and may ultimately result in the
formation of macular holes. Macular holes tend to lead to sudden and often complete loss of
central vision.
Removal of the vitreous (vitrectomy) may improve vitreoretinal traction, but a complete
relief of traction is only achieved if the ILM is removed from the retina in the area around
the macula: At the end of vitrectomy, the surgeon grasps the ILM with a fine forceps and
carefully peels it off the underlying retinal layers. This procedure is extremely delicate,
as the ILM is transparent, extremely thin and in direct contact with highly vulnerable
retinal structures. Vital dyes have been employed to make the ILM more visible and because
some dyes have been described to improve "grip" of the ILM during its extraction. The most
commonly used dye, Indocyanine green (ICG) is not approved for intravitreal use and a
discussion on possible toxic side effects is ongoing. The approved alternative substance
Brilliant blue G is employed only by a minority of vitreoretinal surgeons. It is our
hypothesis, that the popularity of ICG is due to superior staining capacity and a stiffening
effect which may make ILM removal easier for the surgeon.
The first goal of this interdisciplinary and translational project, integrating Medical
physics, Biomedical engineering, Nanosciences, Biochemistry, Neurobiology, Medical Image
analysis and Clinical ophthalmology is to assess and quantify the helpfulness of existing
dyes in terms of staining behavior and their influence on ILM "grip". In a second step, the
project will analyze how new application protocols and the introduction of novel components
to the molecular structure of vital dyes can improve staining as well as "ILM-grip" while
guaranteeing favorable toxicity profiles Hypotheses
1. A novel "Heavy BBG" (BBG D2O) stains the ILM better than conventional BBG. A replacement
of part of the water molecules with Deuterium Oxide (D20) in the BBG solvent increases
the dye's specific gravity. After injection into the vitreous, this new preparation (BBG
D2O) would collect on the retinal surface, increasing local concentration and retinal
exposure. We hypothesize that this alteration of the BBG molecular structure could
improve staining properties without compromising its favorable toxicity profile. This
new BBG has already been introduced by the manufacturer, but its intraoperative
usefulness has not been objectively examined.
2. The use of intraoperative light filters improves the recognizability of the contrasts
generated by vital dyes. Most endoillumination lighting systems are equipped with light
filters, originally intended to reduce intraoperative light toxicity. Anecdotal reports
by numerous surgeons indicate, however, that the use of some filters improves the
recognizability of the stained ILM. The green filter is regarded as particularly useful
for this purpose. A systematic analysis of the effects of light filters on the
usefulness of intravitreal dyes has not been undertaken to date.
3. ICG and TB's photochemical properties improve "ILM grip" through an ILM cross-linking
effect resulting in an alteration of ILM material properties. We expect increased
intra-operative ILM compressive and tensile stiffness and reduced ILM thickness in
Atomic force microscopy examinations, explaining why many surgeons describe facilitated
intraoperative manipulation and extraction of the ILM. BBG is not known to dispose of
photochemical properties and should not influence ILM material properties.
4. Novel Modified ICG preparation stains equally well but is less toxic An alteration of
the molecular structure in a way such that photochemical properties of the substance
would be largely eliminated would strongly reduce oxidative stress and retinal toxicity.
Synthetization of such a preparation is being prepared by our group. Staining properties
are different from the original preparation in that the absorption maximum is shifted
towards shorter wavelengths and the staining effect is bluish rather than green. The
substance's affinity to the ILM its staining strength and its toxicity have not been
studied, to date.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04292912 -
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK2798745 in Participants With Diabetic Macular Edema
|
Phase 1 | |
| Recruiting |
NCT05976139 -
Micropulsed Laser in Patients With Macular Oedema in Retinal Dystrophies
|
N/A | |
| Completed |
NCT03660371 -
ILM Peeling in PDR Patients Undergoing PPV for VH
|
N/A | |
| Completed |
NCT03660345 -
PPV With Internal Limiting Membrane Peeling for Treatment-Naïve DME
|
Phase 3 | |
| Completed |
NCT01660802 -
Safety and Efficacy Study of Dexamethasone in the Treatment of Patients With Macular Edema Following Retinal Vein Occlusion (RVO)
|
Phase 3 | |
| Completed |
NCT01908816 -
An Open-label Extended Clinical Protocol of Ranibizumab to Evaluate Safety and Efficacy in Rare VEGF Driven Ocular Diseases.
|
Phase 3 | |
| Completed |
NCT04592419 -
A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)
|
Phase 3 | |
| Completed |
NCT02867735 -
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of Intravitreal LKA651 in Patients With Macular Edema
|
Phase 1 | |
| Completed |
NCT02623673 -
Simultaneous Therapy With Intravitreal Dexamethasone Implant and Bevacizumab for the Treatment of Macular Edema
|
N/A | |
| Terminated |
NCT01946399 -
Ozurdex Implant for Macular Edema After Treatment Failure With Anti-VEGF
|
N/A | |
| Completed |
NCT01428388 -
Bevacizumab Versus Ranibizumab in Treatment of Macular Edema From Vein Occlusion
|
N/A | |
| Completed |
NCT01231633 -
Comparison of Initial Ozurdex (Dexamethasone Implant) to Avastin (Bevacizumab) for Treatment of Macular Edema Caused by Central Retinal Vein Occlusion (CRVO)
|
N/A | |
| Recruiting |
NCT01023113 -
To Compare Visual Field Impairment in Conventional Double Frequency Nd: YAG Panretinal Photocoagulation With PASCAL Panretinal Photocoagulation
|
N/A | |
| Terminated |
NCT00969293 -
Study to Assess the Safety and Tolerability of a Single Administration of FOV2302 (Ecallantide) in Patients With Macular Edema Associated With Central Retinal Vein Occlusion
|
Phase 1 | |
| Terminated |
NCT00918554 -
Efficacy Study of Methotrexate to Treat Sarcoid-associated Uveitis
|
Phase 4 | |
| Completed |
NCT00970957 -
Safety and Effectiveness of Bevacizumab Intravitreal Injections in the Treatment of Macular Edema Secondary to Retinal Vein Occlusion
|
Phase 3 | |
| Completed |
NCT00476593 -
Retinal OCT and (mfERG) Related to Age, Sex, and the Use of Anti-inflammatory Medications
|
N/A | |
| Completed |
NCT00668239 -
Diffuse Diabetic Maculopathy With Intravitreal Triamcinolone or Laser
|
N/A | |
| Completed |
NCT00411970 -
20- Versus 23- Gauge System for Pars Plana Vitrectomy
|
Phase 4 | |
| Terminated |
NCT01939691 -
Macular Edema Nepafenac vs. Difluprednate Uveitis Trial
|
Phase 4 |